Explore the words cloud of the GEMMA project. It provides you a very rough idea of what is the project "GEMMA" about.
The following table provides information about the project.
|Coordinator Country||Italy [IT]|
|Total cost||14˙225˙757 €|
|EC max contribution||14˙225˙757 € (100%)|
1. H2020-EU.3.1.2. (Preventing disease)
|Duration (year-month-day)||from 2019-01-01 to 2023-12-31|
Take a look of project's partnership.
|1||FONDAZIONE EBRIS||IT (SALERNO)||coordinator||2˙035˙531.00|
|2||NATIONAL UNIVERSITY OF IRELAND GALWAY||IE (Galway)||participant||1˙663˙750.00|
|3||THE GENERAL HOSPITAL CORPORATION||US (BOSTON MA)||participant||1˙256˙468.00|
|4||AZIENDA SANITARIA LOCALE SALERNO||IT (SALERNO)||participant||1˙133˙375.00|
|5||INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT||FR (PARIS CEDEX 07)||participant||1˙060˙617.00|
|6||UNIVERSITEIT UTRECHT||NL (UTRECHT)||participant||881˙116.00|
|7||IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE||UK (LONDON)||participant||832˙812.00|
|8||NUTRICIA RESEARCH BV||NL (UTRECHT)||participant||812˙423.00|
|9||JOHNS HOPKINS UNIVERSITY||US (BALTIMORE)||participant||747˙212.00|
|10||EUFORMATICS OY||FI (ESPOO)||participant||728˙437.00|
|11||TAMPEREEN KORKEAKOULUSAATIO SR||FI (TAMPERE)||participant||558˙125.00|
|12||MEDINOK SPA||IT (VOLLA)||participant||549˙375.00|
|13||BIO MODELING SYSTEMS OU BMSYSTEMS||FR (Paris)||participant||548˙125.00|
|14||CONSIGLIO NAZIONALE DELLE RICERCHE||IT (ROMA)||participant||544˙375.00|
|15||INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE||FR (PARIS)||participant||447˙762.00|
|16||THEOREO SRL||IT (MONTECORVINO PUGLIANO)||participant||426˙250.00|
|17||TAMPEREEN YLIOPISTO||FI (TAMPERE)||participant||0.00|
GEMMA will be the first project to combine a multi-omic approach with robust environmental data to exploit the analysis of the composition and function of the microbiome for personalized treatment and, ultimately, disease interception in infants at risk of Autistic Spectrum Disorders (ASD) . The project will provide solid mechanistic evidence of the disease onset and progression in relation to dynamic changes in abnormal gut microbiota causing epigenetic modifications controlling gut barrier and immune functions, based on the in-depth evaluation of 600 infants at risk observed from birth and followed over time. These data will be integrated with pre-clinical studies to mechanistically link human microbiota composition/function with clinical outcome through humanized murine models transplanted with stools obtained from the ASD proband patient of recruited families. The project will support novel personalized prediction (personalized treatment) and disease interception (prevention) approaches that attempt to modulate gut microbiota to re-establish/maintain immune homeostasis. The biomarkers identified in this project will contribute to a better understanding of the pathogenesis of ASD in at-risk children and the possibility to manipulate the microbiota through pre/pro/symbiotic administration for prevention and treatment, a complete paradigm shift in ASD pathogenesis and early intervention. The identification of specific ASD metabolic phenotypes will further aid to define biomarkers that can be used as diagnostic tools and patient stratification models for other conditions in which the interplay between genome, microbiome and metabolic profile has been suspected or proved. Finally, the project will collect biospecimens from a cohort of 600 infants as risk of ASD observed from birth, generating a unique biobank of 16,000 blood, stool, urine and saliva samples prospectively collected that can be exploited in future multiomic studies.
|OmnomicsNGS v2 release||Demonstrators, pilots, prototypes||2020-04-25 10:50:00|
|Genome, epigenome and immune function interplay summary of hypothesis||Documents, reports||2020-04-25 10:50:00|
|Pre-clinical study ethical approval report||Documents, reports||2020-04-25 10:50:00|
|Updated state of the art report||Documents, reports||2020-04-25 10:50:00|
|Microbiome, metabolome and immune function interplay summary of hypothesis||Documents, reports||2020-04-25 10:50:00|
|Pre-clinical study 3/1 report||Documents, reports||2020-04-25 10:50:00|
|External project website||Websites, patent fillings, videos etc.||2020-04-25 10:50:00|
|Final clinical protocols||Documents, reports||2020-04-25 10:50:00|
|Open data management plan||Open Research Data Pilot||2020-04-25 10:50:00|
Take a look to the deliverables list in detail: detailed list of GEMMA deliverables.
|year||authors and title||journal||last update|
Noemi Di Nanni, Matteo Bersanelli, Francesca Anna Cupaioli, Luciano Milanesi, Alessandra Mezzelani, Ettore Mosca
Network-Based Integrative Analysis of Genomics, Epigenomics and Transcriptomics in Autism Spectrum Disorders
published pages: 3363, ISSN: 1422-0067, DOI: 10.3390/ijms20133363
|International Journal of Molecular Sciences 20/13||2020-04-25|
Leonardo Emberti Gialloreti, Luigi Mazzone, Arianna Benvenuto, Alessio Fasano, Alicia Garcia Alcon, Aletta Kraneveld, Romina Moavero, Raanan Raz, Maria Pia Riccio, Martina Siracusano, Ditza A. Zachor, Marina Marini, Paolo Curatolo
Risk and Protective Environmental Factors Associated with Autism Spectrum Disorder: Evidence-Based Principles and Recommendations
published pages: 217, ISSN: 2077-0383, DOI: 10.3390/jcm8020217
|Journal of Clinical Medicine 8/2||2020-04-25|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GEMMA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GEMMA" are provided by the European Opendata Portal: CORDIS opendata.
Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and EbolaRead More
European platforM to PromOte Wellbeing and HEalth in the woRkplaceRead More
Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response.Read More